Literature DB >> 34224831

Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.

Rabi Murad1, Arabo Avanes2, Xinyi Ma1, Shuhui Geng2, Ali Mortazavi3, Jamil Momand4.   

Abstract

We set out to uncover transcriptome and chromatin landscape changes that occur in HER2 + breast cancer (BC) cells upon acquiring resistance to trastuzumab. RNA-seq analysis was applied to two independently-derived BC cell lines with acquired resistance to trastuzumab (SKBr3.HerR and BT-474HerR) and their parental drug-sensitive cell lines (SKBr3 and BT-474). Chromatin landscape analysis indicated that the most significant increase in accessibility in resistant cells occurs in PPP1R1B within a segment spanning introns 1b through intron 3. Footprint analysis of this segment revealed that FoxJ3 (within intron 2) and Pou5A1/Sox2 (within inton 3) transcription factor motifs are protected in resistant cells. Overall, 344 shared genes were upregulated in both resistant cell lines relative to their parental counterparts and 453 shared genes were downregulated in both resistant cell lines relative to their parental counterparts. In resistant cells, genes associated with autophagy and mitochondria organization are upregulated and genes associated with ribosome assembly and cell cycle are downregulated relative to parental cells. The five top upregulated genes in drug-resistant breast cancer cells are APOD, AZGP1, ETV5, ALPP, and PPP1R1B. This is the first report of increased chromatin accessibility within PPP1R1B associated with its t-Darpp transcript increase, and points to a possible mechanism for its activation in trastuzumab-resistant cells. Published by Elsevier B.V.

Entities:  

Keywords:  ATAC-seq; FoxJ3; Herceptin; PPP1R1B; Pou5A1; Sox2; breast cancer; differentially expressed genes; drug resistance; trastuzumab

Year:  2021        PMID: 34224831     DOI: 10.1016/j.gene.2021.145808

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

1.  Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.

Authors:  Xiaokai Ding; Amanda C Sharko; Martina S J McDermott; Gary P Schools; Alexander Chumanevich; Hao Ji; Jing Li; Li Zhang; Zachary T Mack; Vitali Sikirzhytski; Michael Shtutman; Laura Ivers; Norma O'Donovan; John Crown; Balázs Győrffy; Mengqian Chen; Igor B Roninson; Eugenia V Broude
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

2.  MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.

Authors:  Mingliang Zhang; Zhixiang Li; Xianfu Liu
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

3.  Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.

Authors:  Sanghoon Lee; Hatice Ulku Osmanbeyoglu
Journal:  Breast Cancer Res       Date:  2022-07-29       Impact factor: 8.408

4.  Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells.

Authors:  Laura Kuhlmann; Meinusha Govindarajan; Salvador Mejia-Guerrero; Vladimir Ignatchenko; Lydia Y Liu; Barbara T Grünwald; Jennifer Cruickshank; Hal Berman; Rama Khokha; Thomas Kislinger
Journal:  J Proteome Res       Date:  2022-08-18       Impact factor: 5.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.